Structural outcomes in the sacroiliac joint after ixekizumab treatment for 16 weeks in patients with active non-radiographical axial spondyloarthritis stratified by gender, HLA-B27, and baseline MRI inflammation

Walter P.  Maksymowych; X Baraliakos; Robert G. Lambert; Robert B. M. Landewé; D Sandoval; Hilde Carlier; Jeffrey Lisse; Xiao Li; M Hojnk; Mikkel Østergaard

Structural outcomes in the sacroiliac joint after ixekizumab treatment for 16 weeks in patients with active non-radiographical axial spondyloarthritis stratified by gender, HLA-B27, and baseline MRI inflammation

Walter P. Maksymowych, X Baraliakos, Robert G. Lambert, Robert B. M. Landewé, D Sandoval, Hilde Carlier, Jeffrey Lisse, Xiao Li, M Hojnk, Mikkel Østergaard

Afdeling for Rygkirurgi, Led- og Bindevævssygdomme

Abstract

Background Ixekizumab (IXE) has demonstrated clinical efficacy in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) together with significant repair of structural lesions in the sacroiliac joint (SIJ) on MRI. There is, however, a paucity of data as to which patients may be most responsive.

Originalsprog	Engelsk
Publikationsdato	2022
Status	Udgivet - 2022
Begivenhed	EULAR 2022 - Copenhagen Varighed: 1 jun. 2022 → 4 jun. 2022

Konference

Konference	EULAR 2022
By	Copenhagen
Periode	01/06/2022 → 04/06/2022

Fingeraftryk

Dyk ned i forskningsemnerne om 'Structural outcomes in the sacroiliac joint after ixekizumab treatment for 16 weeks in patients with active non-radiographical axial spondyloarthritis stratified by gender, HLA-B27, and baseline MRI inflammation'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Maksymowych, W. P., Baraliakos, X., Lambert, R. G., Landewé, R. B. M., Sandoval, D., Carlier, H., Lisse, J., Li, X., Hojnk, M., & Østergaard, M. (2022). Structural outcomes in the sacroiliac joint after ixekizumab treatment for 16 weeks in patients with active non-radiographical axial spondyloarthritis stratified by gender, HLA-B27, and baseline MRI inflammation. Annals of the Rheumatic Diseases 81 Suppl 1: 399. Abstract fra EULAR 2022, Copenhagen.

Structural outcomes in the sacroiliac joint after ixekizumab treatment for 16 weeks in patients with active non-radiographical axial spondyloarthritis stratified by gender, HLA-B27, and baseline MRI inflammation. / Maksymowych, Walter P.; Baraliakos, X; Lambert, Robert G. et al.
2022. Annals of the Rheumatic Diseases 81 Suppl 1: 399 Abstract fra EULAR 2022, Copenhagen.

Publikation: Konferencebidrag › Konferenceabstrakt til konference › Forskning › peer review

Maksymowych, WP, Baraliakos, X, Lambert, RG, Landewé, RBM, Sandoval, D, Carlier, H, Lisse, J, Li, X, Hojnk, M & Østergaard, M 2022, 'Structural outcomes in the sacroiliac joint after ixekizumab treatment for 16 weeks in patients with active non-radiographical axial spondyloarthritis stratified by gender, HLA-B27, and baseline MRI inflammation', EULAR 2022, Copenhagen, 01/06/2022 - 04/06/2022 s. Annals of the Rheumatic Diseases 81 Suppl 1: 399.

@conference{2758bb2c3ca749369b24798c240f684c,

title = "Structural outcomes in the sacroiliac joint after ixekizumab treatment for 16 weeks in patients with active non-radiographical axial spondyloarthritis stratified by gender, HLA-B27, and baseline MRI inflammation",

abstract = "Background: Ixekizumab (IXE) has demonstrated clinical efficacy in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) together with significant repair of structural lesions in the sacroiliac joint (SIJ) on MRI. There is, however, a paucity of data as to which patients may be most responsive.",

author = "Maksymowych, {Walter P.} and X Baraliakos and Lambert, {Robert G.} and Landew{\'e}, {Robert B. M.} and D Sandoval and Hilde Carlier and Jeffrey Lisse and Xiao Li and M Hojnk and Mikkel {\O}stergaard",

note = "COPECARE; EULAR 2022 ; Conference date: 01-06-2022 Through 04-06-2022",

year = "2022",

language = "English",

pages = "Annals of the Rheumatic Diseases 81 Suppl 1: 399",

}

TY - ABST

T1 - Structural outcomes in the sacroiliac joint after ixekizumab treatment for 16 weeks in patients with active non-radiographical axial spondyloarthritis stratified by gender, HLA-B27, and baseline MRI inflammation

AU - Maksymowych, Walter P.

AU - Baraliakos, X

AU - Lambert, Robert G.

AU - Landewé, Robert B. M.

AU - Sandoval, D

AU - Carlier, Hilde

AU - Lisse, Jeffrey

AU - Li, Xiao

AU - Hojnk, M

AU - Østergaard, Mikkel

N1 - COPECARE

PY - 2022

Y1 - 2022

N2 - Background: Ixekizumab (IXE) has demonstrated clinical efficacy in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) together with significant repair of structural lesions in the sacroiliac joint (SIJ) on MRI. There is, however, a paucity of data as to which patients may be most responsive.

AB - Background: Ixekizumab (IXE) has demonstrated clinical efficacy in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) together with significant repair of structural lesions in the sacroiliac joint (SIJ) on MRI. There is, however, a paucity of data as to which patients may be most responsive.

M3 - Conference abstract for conference

SP - Annals of the Rheumatic Diseases 81 Suppl 1: 399

T2 - EULAR 2022

Y2 - 1 June 2022 through 4 June 2022

ER -